← All trials
NCT05928546
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 20, 2023
- Primary completion
- Nov 20, 2023
- Completion date
- Nov 20, 2023
- First posted
- Jul 3, 2023
- Last posted
- Oct 10, 2023
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Assiut UniversityLead sponsor
- Assiut UniversityOverall official - principal investigator
- Assiut UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.